Retatrutide has produced substantial weight-loss and metabolic results in clinical trials, but does that mean retatrutide is safe?

The evidence so far provides an increasingly detailed picture. Phase 2 and Phase 3 clinical trials have now studied retatrutide extensively. Gastrointestinal effects such as nausea, diarrhoea, constipation and vomiting are among the most consistently reported adverse events. Researchers have also observed increased heart rate and altered skin sensations. Meanwhile, researchers continue to monitor serious adverse events and treatment discontinuations.

However, retatrutide remains an investigational drug. Regulators have not approved it for general therapeutic use. Researchers are also still studying important questions about its longer-term safety.

There is an important distinction between retatrutide administered under controlled clinical-trial conditions and unapproved products marketed online as “retatrutide”. We cannot automatically apply clinical-trial safety findings to products with unknown identity, purity, concentration or manufacturing quality.

So, is retatrutide safe? The most accurate answer requires looking at what the clinical evidence actually shows. We also need to consider how that evidence has developed and what researchers still do not know.

What Do We Know About Retatrutide’s Safety So Far?

Retatrutide is an investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1 and glucagon receptors. Our separate guide to what retatrutide does explains that mechanism and the clinical effects under investigation in more detail.

One of the foundational safety studies was the Phase 2 obesity trial, which involved 338 adults and 48 weeks of treatment. Researchers reported adverse events in 73% to 94% of participants across the retatrutide groups, compared with 70% receiving placebo. The 8 mg and 12 mg groups had the highest incidence. Gastrointestinal events occurred most frequently and were predominantly mild to moderate.

The evidence base has since progressed into Phase 3.

The TRANSCEND-T2D-1 trial added peer-reviewed Phase 3 safety data from 537 adults with type 2 diabetes treated for 40 weeks. Participants receiving retatrutide most frequently experienced mild to moderate gastrointestinal events, which subsided over time. Adverse events led 2% to 5% of retatrutide participants to discontinue treatment, compared with 0% of placebo participants. Researchers reported no severe hypoglycaemia. Two participants in the 4 mg group died, but investigators assessed both deaths as unrelated to study treatment.

The larger TRIUMPH-1 trial has substantially expanded the obesity safety dataset. Lilly reported that its 80-week placebo-controlled trial randomised 2,339 participants. The current ClinicalTrials.gov record lists actual enrolment of 2,335.

That growing evidence base matters. Researchers cannot establish a drug’s safety profile from one trial or one adverse-event rate. Instead, they look for patterns as more participants receive treatment for longer periods. Larger studies can also reveal less common risks.

What Safety Issues Have Been Observed With Retatrutide?

The most consistent finding across the clinical programme remains gastrointestinal tolerability.

The same broad pattern seen in Phase 2 continued in Phase 3. In TRIUMPH-1 topline results released in May 2026, Lilly reported nausea across the three retatrutide dose groups. Rates were 28.6%, 38.4% and 42.4% at 4 mg, 9 mg and 12 mg respectively, compared with 14.8% for placebo. Vomiting occurred in 10.6%, 22.8% and 25.3%, compared with 4.8% with placebo. Diarrhoea and constipation were also common.

Rather than reproduce the complete adverse-event breakdown here, our separate analysis of retatrutide side effects examines the individual effects and their frequency. It also examines their relationship with dose and compares findings across Phase 2 and Phase 3 trials.

Heart rate and cardiovascular findings

The Phase 2 obesity trial found a dose-dependent increase in heart rate through approximately 24 weeks. Heart rate subsequently declined. Researchers reported predominantly mild to moderate cardiac arrhythmias. One participant who was also receiving ondansetron experienced a severe prolonged-QT event.

That does not establish that retatrutide causes adverse cardiovascular outcomes. It does, however, reinforce why longer-term cardiovascular evidence remains important.

Dysesthesia and altered skin sensation

Altered skin sensation has appeared at more than one stage of development.

In Phase 2, researchers reported cutaneous hyperesthesia or skin sensitivity in 7% of retatrutide-treated participants and 1% of placebo participants. None of these events were severe or serious. None resulted in treatment discontinuation.

TRIUMPH-1 subsequently reported dysesthesia in 5.1%, 12.3% and 12.5% of participants receiving 4 mg, 9 mg and 12 mg retatrutide respectively. The placebo group reported a rate of 0.9%. Lilly described these events as generally mild to moderate and reported that most participants continued treatment.

Its appearance in both earlier and newer evidence makes it a finding worth following as the Phase 3 programme develops.

Pancreatic, gallbladder and liver findings

Less common events require more cautious interpretation.

The Phase 2 obesity trial reported one serious case of acute pancreatitis, one case of cholecystitis and two cases of cholelithiasis. Researchers also recorded transient ALT increases above three times the upper limit of normal in 1% of retatrutide-treated participants. However, mean ALT and AST levels remained unchanged or fell by week 48.

An adverse event occurring during a clinical trial does not automatically establish that the investigational drug caused it. Researchers must consider its timing, incidence, comparator data and the wider evidence base.

How Common Are Serious Adverse Events?

Serious adverse events and treatment discontinuation provide information beyond whether a participant experienced any side effect.

In the Phase 2 obesity trial, 13 participants experienced 15 serious adverse events. Serious adverse events affected 4% of retatrutide-treated participants and 4% of placebo participants. One participant died from drowning, which the site investigator assessed as unrelated to retatrutide.

Adverse events caused 6% to 16% of participants across the retatrutide groups to discontinue treatment, compared with none receiving placebo. Gastrointestinal events were the most common reason.

In TRIUMPH-1, Lilly reported adverse-event discontinuation rates of 4.1%, 6.9% and 11.3% at 4 mg, 9 mg and 12 mg respectively. The corresponding placebo rate was 4.9%.

At the subsequent TRIUMPH-1 scientific presentation, Lilly reported serious adverse events in 7.7% to 10.5% of participants receiving retatrutide. The placebo group had a rate of 5.5%. Gastrointestinal adverse events were the most common reason for treatment discontinuation.

These figures put common side effects into context. They show how often adverse events met the criteria for serious events or led participants to stop treatment.

What Has Phase 3 Added to the Safety Picture?

One useful way to interpret the evidence is to ask whether the safety picture changes as the clinical programme grows.

Lilly reported 2,339 participants randomised in its May 2026 results. The current ClinicalTrials.gov record lists actual enrolment of 2,335.

The key point is that Phase 3 has largely reinforced rather than overturned the earlier safety picture.

Gastrointestinal adverse events remain prominent. Higher doses generally produce more tolerability problems and greater treatment discontinuation. Dysesthesia has persisted as a recognisable finding. Larger trials are also giving researchers substantially more information about serious adverse events and longer exposure.

The TRANSCEND-T2D-2 trial adds another perspective by comparing retatrutide directly with semaglutide (Ozempic). Our retatrutide vs Ozempic analysis examines the reported differences in adverse events and treatment discontinuation rates between the two treatments.

The complete TRIUMPH-1 results were published in the New England Journal of Medicine on 29 September 2026.

What Don’t We Know Yet About Retatrutide Safety?

The biggest remaining limitation is long-term evidence.

Even large Phase 3 trials cannot immediately identify every uncommon event. Nor can they establish what happens after several years of exposure.

The ongoing TRIUMPH-Outcomes trial is designed to address part of that gap. ClinicalTrials.gov lists an estimated enrolment of 10,000 participants with established atherosclerotic cardiovascular disease and/or chronic kidney disease. Researchers designed the Phase 3 study to evaluate major cardiovascular and kidney outcomes. ClinicalTrials.gov currently lists an estimated primary completion date in 2029. Researchers have not yet posted results.

Rare adverse events are another limitation. Very infrequent events may only become apparent after substantially larger numbers of people receive the drug.

Retatrutide also lacks the broad post-marketing safety experience available for medicines that regulators have approved and people have routinely used for years.

These gaps are why “safe” cannot yet be treated as a settled binary conclusion.

Is Clinical-Trial Retatrutide the Same as Retatrutide Sold Online?

No. This is a separate safety question and an especially important distinction for people researching Retatrutide Australia.

The clinical evidence discussed above comes from controlled studies using investigational retatrutide under defined research protocols.

The TGA guidance on unapproved peptides specifically identifies retatrutide among unapproved peptide products promoted or supplied in Australia. The TGA has not evaluated products outside the Australian Register of Therapeutic Goods for safety, quality or effectiveness.

Our analysis of whether retatrutide is available in Australia explains the current TGA status and what online availability actually means.

In June 2026, the TGA and Chief Medical Officer also warned about serious adverse effects associated with unapproved peptide products. These included liver damage, severe allergic reactions requiring hospitalisation, inflammation and other complications requiring medical attention. Importantly, the warning applies to unapproved peptide products as a category. It does not show that authenticated clinical-trial retatrutide caused each of those effects.

The distinction is therefore straightforward. Clinical-trial safety data tell us about authenticated investigational retatrutide used under controlled study conditions. They do not establish the identity, purity, sterility, concentration or safety of a product simply because its label says “retatrutide”.

So, Is Retatrutide Safe?

The available evidence supports a more nuanced answer than either “yes” or “no”.

Retatrutide now has a growing safety dataset from Phase 2 and Phase 3 clinical trials. Gastrointestinal adverse events are the most consistent finding, particularly at higher doses. Researchers have also observed increased heart rate, dysesthesia and less common pancreatic and gallbladder events.

Serious adverse events have occurred. However, the available evidence does not support assuming that retatrutide caused every serious event that occurred during treatment. Treatment-discontinuation rates also vary by dose and trial and provide an important measure of tolerability.

The bigger limitation is that retatrutide remains investigational. Researchers are still studying its longer-term cardiovascular, kidney and broader safety profile. It also lacks the years of post-approval exposure available for established medicines.

The current evidence therefore allows researchers to describe an emerging safety profile with increasing confidence. It does not yet justify describing retatrutide as definitively or universally safe.

For Australians, that conclusion applies specifically to investigational retatrutide studied under controlled clinical-trial conditions. It should not extend to unapproved products supplied outside those trials.

Frequently Asked Questions

Is retatrutide safe to take?

Phase 2 and Phase 3 clinical trials have now generated an increasingly substantial safety dataset for retatrutide. However, retatrutide remains investigational, and researchers are still studying important longer-term outcomes. The evidence therefore describes its emerging safety profile rather than establishing that retatrutide is safe for general or unsupervised use.

Is retatrutide safe to use long term?

Researchers have not yet established its long-term safety. They continue to generate longer-term evidence through studies including TRIUMPH-Outcomes. The trial is expected to evaluate cardiovascular and kidney outcomes in approximately 10,000 participants through around 2029.

What are the main safety concerns with retatrutide?

Clinical trials have most consistently reported gastrointestinal adverse events, particularly nausea, diarrhoea, constipation and vomiting. Researchers are also monitoring increased heart rate, dysesthesia and less common pancreatic and gallbladder events.

Has retatrutide been approved as safe by the TGA?

No. Retatrutide is not an approved therapeutic product in the Australian Register of Therapeutic Goods. The TGA includes retatrutide among unapproved peptide products and has not evaluated these products for safety, quality or effectiveness.

Are products sold online as retatrutide the same as retatrutide used in clinical trials?

We cannot assume that they are. Clinical-trial evidence relates to authenticated investigational retatrutide administered under controlled protocols. Products supplied outside those trials may lack independently established identity, purity, concentration, sterility or manufacturing quality.

Research Sources

Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine, 2023.  

Bajaj HS, et al. Efficacy and Safety of Retatrutide in People With Type 2 Diabetes and Inadequate Glycaemic Control With Diet and Exercise TRANSCEND-T2D-1. The Lancet, 2026.

ClinicalTrials.gov. TRIUMPH-1, NCT05929066.  

Eli Lilly and Company. TRIUMPH-1 Phase 3 Topline Results, May 2026.

Eli Lilly and Company. TRIUMPH-1 Phase 3 Scientific Presentation, ADA 2026.

ClinicalTrials.gov. TRIUMPH-Outcomes, NCT06383390.  

Therapeutic Goods Administration. Understanding Your Responsibilities When Importing, Compounding and Supplying Unapproved Peptide Products, April 2026.

Therapeutic Goods Administration and Australian Chief Medical Officer. Concerns Regarding the Public Health Risks Associated With Unapproved Peptide Products, June 2026.